Eccogene's $60M milestone from AstraZeneca: The payment arrived after Eccogene met several milestones, including dosing the first ...

Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment.

Evotec announced in May of 2022 that the Company has further extended and expanded its partnership with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec ...

Evotec (EVO) announced progress within the company’s strategic partnership with Bristol Myers Squibb (BMY) relating to building a molecular glue-based pipeline. Key scientific achievements drive the ...

Evotec International GmbH and Nosopharm SAS have jointly described odilorhabdin analogues reported to be useful for the treatment of multidrug-resistant bacterial infections.